Open Access

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib

  • Authors:
    • Zelong Yang
    • Jie Zhang
    • Xiaotong Lin
    • Di Wu
    • Guixi Li
    • Chunlian Zhong
    • Lei Fang
    • Peng Jiang
    • Liangyu Yin
    • Leida Zhang
    • Ping Bie
    • Chuan‑Ming Xie
  • View Affiliations

  • Published online on: April 4, 2019     https://doi.org/10.3892/or.2019.7098
  • Pages: 3257-3269
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sorafenib remains the standard care for patients with hepatocellular carcinoma (HCC) even though it has low antitumor efficacy. Protein neddylation is abnormally activated in many types of human cancer. However, whether dysregulation of neddylation is involved in HCC progression and whether targeting neddylation sensitizes HCC cells to sorafenib need to be ascertained. In the present study, it was demonstrated that high expression of neddylation components, neural precursor cell expressed, developmentally downregulated 8 (NEDD8) and NEDD8‑activating enzyme 1 (NAE1), were associated with poor survival of patients with HCC. Inhibition of neddylation by MLN4924, a small‑molecule inhibitor of NAE1, significantly inhibited HCC growth, reduced clonogenic survival, increased apoptosis, and decreased migration capacity. Sorafenib alone exhibited minimal anticancer efficacy. However, a combination of sorafenib with MLN4924 at a low concentration significantly enhanced the inhibition of cell proliferation and migration as well as the induction of apoptosis induced by sorafenib. In vivo HCC xenograft mouse models also showed that MLN4924 increased the antitumor efficacy of sorafenib. Mechanistically, MLN4924 enhanced the antitumor activity of sorafenib in HCC cells via upregulation of cullin‑RING E3 ubiquitin ligase (CRL)/Skp1‑Cullin1‑F box (SCF) E3 ubiquitin ligase substrates p21, p27, Deptor and IκBɑ. Taken together, these findings suggest that combination therapy of MLN4924 with sorafenib appears to present an additive effect with a maximal in the treatment of HCC.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 41 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yang, Z., Zhang, J., Lin, X., Wu, D., Li, G., Zhong, C. ... Xie, C. (2019). Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib. Oncology Reports, 41, 3257-3269. https://doi.org/10.3892/or.2019.7098
MLA
Yang, Z., Zhang, J., Lin, X., Wu, D., Li, G., Zhong, C., Fang, L., Jiang, P., Yin, L., Zhang, L., Bie, P., Xie, C."Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib". Oncology Reports 41.6 (2019): 3257-3269.
Chicago
Yang, Z., Zhang, J., Lin, X., Wu, D., Li, G., Zhong, C., Fang, L., Jiang, P., Yin, L., Zhang, L., Bie, P., Xie, C."Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib". Oncology Reports 41, no. 6 (2019): 3257-3269. https://doi.org/10.3892/or.2019.7098